Payment overview · 2025
General Payments
$10,358.06
37 reported records · 13 companies
Healthcare provider profile · identity verified
Mitchell Gareth Isaac, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WINSTON SALEM, NC · NPI 1629283908
Verified facts
What the public records show
CMS Open Payments records show Mitchell Gareth Isaac, MD received $10,358.06 in general payments during 2025 across 37 reported records.
Lilly USA, LLC accounted for 85.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Botox, Qulipta, Tysabri, Ubrelvy, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tysabri by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zeposia by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $8,898.36 | 85.9% | 5 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $373.48 | 3.6% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $234.10 | 2.3% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $195.89 | 1.9% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $183.68 | 1.8% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $135.91 | 1.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $109.94 | 1.1% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.76 | 0.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.98 | 0.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $36.39 | 0.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.83 | 0.3% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $30.37 | 0.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.37 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $8,200.00 | 2 |
| Food and Beverage | $1,507.79 | 34 |
| Travel and Lodging | $650.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $8,248.09 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $207.74 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $195.89 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $128.13 | 2 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $109.94 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $63.76 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $43.98 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $36.39 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $32.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BOTOX botox |
2025 | Botox | 2024 | 61 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 47 | exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 41 | exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 794 | 230 |
| Duloxetine Hcl | Duloxetine Hcl | 415 | 115 |
| Pregabalin | Pregabalin | 280 | 86 |
| Aimovig Autoinjector | Erenumab-Aooe | 193 | 33 |
| Primidone | Primidone | 190 | 51 |
| Topiramate | Topiramate | 181 | 55 |
| Amitriptyline Hcl | Amitriptyline Hcl | 170 | 62 |
| Donepezil Hcl | Donepezil Hcl | 153 | 46 |
| Levetiracetam | Levetiracetam | 149 | 45 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 145 | 37 |
| Memantine Hcl | Memantine Hcl | 132 | 38 |
| Emgality Pen | Galcanezumab-Gnlm | 113 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 22 |
| Nurtec Odt | Rimegepant Sulfate | 80 | 16 |
| Oxcarbazepine | Oxcarbazepine | 75 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 72 | 27 |
| Rizatriptan | Rizatriptan Benzoate | 67 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 63 | 21 |
| Botox | Onabotulinumtoxina | 61 | 20 |
| Baclofen | Baclofen | 53 | 18 |
| Lacosamide | Lacosamide | 50 | 15 |
| Qulipta | Atogepant | 47 | 13 |
| Prednisone | Prednisone | 46 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 11 |
| Ubrelvy | Ubrogepant | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Amantadine | Amantadine Hcl | 36 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 15 |
| Rasagiline Mesylate | Rasagiline Mesylate | 36 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 35 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 35 | 15 |
| Zonisamide | Zonisamide | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | 14 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Levetiracetam Er | Levetiracetam | 25 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dalfampridine Er | Dalfampridine | 16 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Fingolimod | Fingolimod Hcl | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Tysabri | Natalizumab | 13 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 13 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Keppra Xr | Levetiracetam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Austedo Xr | Deutetrabenazine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,358.06 · 37 records | Lilly USA, LLC | AUSTEDO XR, BOTOX, BRIUMVI, General - Pain Management, KESIMPTA, KISUNLA, Leqembi, Mavenclad, QULIPTA, TYSABRI, UBRELVY, VUMERITY, VYEPTI, VYVGART HYTRULO, ZEPOSIA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error